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Abstract
Abnormal aggregation of tau in the brain is a major contributing factor in various neurodegenerative diseases. The
role of tau phosphorylation in the pathophysiology of tauopathies remains unclear. Consequently, it is important to
be able to accurately and specifically target tau deposits in vivo in the brains of patients. The advances of molecular
imaging in the recent years have now led to the recent development of promising tau-specific tracers for positron
emission tomography (PET), such as THK5317, THK5351, AV-1451, and PBB3. These tracers are now available
for clinical assessment in patients with various tauopathies, including Alzheimer’s disease, as well as in healthy subjects.
Exploring the patterns of tau deposition in vivo for different pathologies will allow discrimination between
neurodegenerative diseases, including different tauopathies, and monitoring of disease progression. The
variety and complexity of the different types of tau deposits in the different diseases, however, has resulted
in quite a challenge for the development of tau PET tracers. Extensive work remains in order to fully characterize the
binding properties of the tau PET tracers, and to assess their usefulness as an early biomarker of the underlying
pathology. In this review, we summarize recent findings on the most promising tau PET tracers to date, discuss what has
been learnt from these findings, and offer some suggestions for the next steps that need to be achieved in a near future.
Keywords: Tau, Positron emission tomography imaging, Neurodegenerative diseases, Tracer development, Biomarker,
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Background
The hyperphosphorylation and abnormal aggregation of
tau, a microtubule-associated protein essential to neur-
onal stability and functioning, is implicated in various
neurodegenerative diseases, labelled as tauopathies. The
most common of these is Alzheimer’s disease (AD) [1].
One of the main pathological hallmarks of AD, along
with the formation of amyloid-beta (Aβ) plaques, is the
aggregation of tau into paired helical filaments (PHFs)
and, subsequently, into neurofibrillary tangles (NFTs).
Neuropathological studies have indicated that the re-
gional distribution of NFTs follows a stereotypical pat-
tern in AD, defined according to six successive “Braak
stages” [2]: in the first two stages, NFTs are limited to
the transentorhinal region (I-II), before spreading to
limbic (III-IV), and isocortical association areas (V-VI).
Other types of tau deposits are characteristic of various
tauopathies. These deposits exhibit distinct regional
distributions in the diseased brain [3], and may be com-
posed of different tau isoforms. Indeed, there are six
different isoforms of tau, formed by alternative mRNA
splicing of the microtubule-associated protein tau
(MAPT) gene. More importantly, the inclusion or exclu-
sion of the exon 10 results in either 3 repeats (3R) or 4
repeats (4R) of the microtubule binding domain being
transcribed in the tau protein, respectively [4]. While the
3R/4R ratio is 1:1 under physiological conditions and in
patients with AD, tangle predominant senile dementia
and chronic traumatic encephalopathy, 3R isoforms are
dominant in Pick’s disease and 4R isoforms are domin-
ant in corticobasal degeneration (CBD), progressive
supranuclear palsy (PSP) and argyrophilic grain disease
[5]. The role of tau aggregation in the pathophysiology
of these neurodegenerative diseases, however, remains
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unclear. This is why the accurate, specific targeting of
tau deposits in vivo in the brain would be highly valu-
able. However, this has historically been a formidable
challenge for the scientific community.
Until very recently, it was only possible to observe tau
deposits by immunohistochemistry in post-mortem tis-
sue using specific antibodies, and the load of tau protein
in the brain was only able to be measured in vivo using
invasive indirect methods such as measuring the con-
centration of the protein (total- and phospho-tau) in the
cerebrospinal fluid (CSF). Because tau – unlike Aβ pla-
ques – aggregates primarily intracellularly (Fig. 1), it
may be more difficult to access in vivo. However, over
the past 5 years, a great effort has been ongoing to de-
velop selective tau tracers for positron emission tomog-
raphy (PET) imaging [6]. The emergence of promising
tau-specific PET tracers, which are now available for
clinical evaluation, has been a major breakthrough in re-
search on AD and other related diseases. Specifically, it
holds promise for exploring the regional patterns of tau
deposition in vivo in different pathologies, discrimin-
ation between neurodegenerative diseases, and monitor-
ing the spread of tau along disease progression. In
addition, the combination of these tau tracers with other
existing biomarkers bears great potential to help, in the
times to come, discriminate between different patholo-
gies, and, possibly, different tauopathies.
There is a fast increasing number of publications
reporting findings on the recently developed tau PET
tracers (Fig. 2). In this review, we summarize and discuss
what has been learnt so far and suggest possible direc-
tions for the near future in tau imaging.
Main text
Development of tau-specific tracers
In addition to the characteristics required for a radio-
tracer to be a good candidate for a PET tracer [7–9], tar-
geting cerebral tau represents an even greater challenge,
for several reasons [10]. For example, tau is located both
extra- and intra-cellularly, and hence the tracer must be
able to cross the cell membrane. Over the past decade,
several molecules have been suggested as potential tau
PET tracers but many of those lacked sufficient specifi-
city and selectivity [11, 12]. Based on both in vitro and
in vivo results, three families of radiotracers have to date
shown promise as specific tau PET tracers: the aryquino-
line derivatives THK5117 (and the (S)-form THK5317)
and THK5351, developed at Tohoku University, Japan
Fig. 1 Tau pathology in relation to other pathological features in Alzheimer’s disease
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[13–16]; the pyrido-indole derivative AV-1451 (also
known as T807 and Flortaucipir), owned by Eli Lilly
and originally developed by Siemens [17, 18]; and the
phenyl/pyridinyl-butadienyl-benzothiazole/benzothiazolium
derivative PBB3 (Chiba, Japan), derived from the same
tracer family as the Aβ ligand Pittsburgh Compound B
(PIB) [19, 20] (see Fig. 3 for chemical structures). This
review focuses on these three families.
Preclinical evaluation of the tau-specific tracers
Evaluation of tracers in vitro in brain tissue and ex vivo in
animal model
The in vitro binding affinities of the promising tracers
mentioned above have been well described in the litera-
ture, and the findings are summarized in Table 1. The
binding affinity to tau deposits was determined using in
vitro binding assays in AD brain homogenates and/or
autoradiographies, depending on the tracer [14, 15, 21–24].
All tracers showed good affinity and exhibited a binding
pattern on autoradiograms in human AD brain tissue,
similar to the pattern of tau deposits revealed by immuno-
staining (Fig. 4) [15, 18, 24–28]. In addition, no selectivity
towards Aβ was found when comparing to amyloid tracers
[15, 18, 22–24, 26, 28–30]. A recent study reported that
the binding pattern of [18F]AV-1451 corresponded better
with the immunostaining pattern of some antibodies than
others, suggesting that AV-1451 binds preferentially to
mature tangles rather than pretangles or extracellular
“ghost” tangles [31]. This illustrates that morphological
differences may affect the binding intensity of tau tracers.
Furthermore, several derivatives have been developed,
especially in the THK family, with the aim of improving
their specificity. With the same goal, studies have com-
pared the specificity of the enantiomeric forms of THK
tracers. The results indicated that the (S)-forms had
better pharmacokinetic and binding properties, as well
as lower white matter binding than the corresponding
(R)-forms, making the (S)-forms more suitable for in
vivo investigations [14, 32].
In complement to in vitro investigations, ex vivo
biodistribution and metabolite analyses have been per-
formed for the three families of tau PET tracers. All the
tracers showed rapid brain uptake and clearance through
the liver, kidney and intestine [18, 20, 21]. However, in
contrast to the other tracers, radioactive metabolites of
[11C]PBB3 were found to enter the brain in a mouse
model [20]. In addition, PBB3 is photoisomerized by
fluorescent light, limiting the feasibility of in vitro ex-
perimentation and in vivo acquisitions with this tracer.
Direct comparison of tracers: There is a noticeable
lack of head-to-head comparisons of the in vitro proper-
ties of tracers from different chemical families. To date,
only one study compared the binding properties of
[18F]AV-1451 and [11C]PBB3 [33]. Using brain tissue
from several tauopathies, the authors reported partially
distinct binding distribution of the tracers, as well as dis-
tinct selectivity for diverse types of tau deposits, with the
binding of [11C]PBB3 to lesions comprised of 4-repeat
or 3-repeat tau isoforms higher than that of [18F]AV-
1451. In another study comparing the binding properties
of [3H]AV-1451 and [3H]THK523 (an antecessor of
THK5117 and THK5351) Cai et al. [34] reported that
the two tracers showed a high affinity for distinct bind-
ing sites on the NFTs. Further investigations showed that
those binding sites were different again from the
thioflavine-T site targeted by [3H]PIB. Lastly, another in
vitro study comparing [18F]T808 (a benzimidazo-
pyrimidine derivative from the same family as AV-1451)
Fig. 2 Number of publications on tau PET tracers in the recent years. The graph starts from the first publication on a tau tracer; each bar plot
represents a period of three months
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with THK5105 (another antecessor of THK5117, and
THK5351) suggested that the two tracers exhibited affin-
ity to similar brain regions [29]. However, the binding
properties of THK5117 and THK5351 have not yet been
compared to AV-1451 and PBB3 binding in the same
sample. Testing each of these tracers within the same
cases would greatly improve the field’s knowledge re-
garding the affinity and specificity of tau tracers.
In vitro binding in different tauopathies: Studying the
in vitro binding of available tau PET tracers in different
non-AD tauopathies appears essential to our under-
standing of their specific targets in these diseases. This
was investigated for PBB3 using autofluorescence bind-
ing studies, which showed specific binding to tau lesions
in PSP, CBD and Pick’s disease, as confirmed by AT8 tau
immunostaining [28, 33]. Similar results have been ob-
served for THK5351 in both CBD and PSP [35, 36]. In
contrast, mixed findings have been reported on the
binding of AV-1451 in non-AD. While specific binding
was reported to be absent or minimal in CBD and PSP,
as well as in Lewy body-related cases [31, 33, 37, 38],
and multiple system atrophy [31, 37], results for cases
with Pick’s disease were conflicting: Marquié et al. [37]
reported no specific binding of AV-1451, while Ono et al.
[33] observed weak specific binding and Sander et al. [38]
moderate specific binding in Pick’s disease brain tissue.
The latter study also showed specific binding in two cases
with mutations of the MAPT gene (FTDP-17) that exhib-
ited 4R tau deposits, suggesting that specific binding
may not be limited to 3R + 4R deposits. Both Lowe et
al. [31] and Sander et al. [38] agreed, however, that
specific binding in non-AD pathology is, whenever
observed, less prevalent than in AD pathology. In
addition, good correspondence was reported between
visual assessment of AV-1451 binding and tau immu-
nostaining [31, 37], although no significant correlation
was found between AV-1451 binding and AT8 stain-
ing on quantitative assessment unless all tauopathies
were combined in the analysis [38]. This further illus-
trates that not only morphological but also isoform
differences could affect the binding intensity of tau
tracers [31].
In vitro binding to non-pathological features: Marquié
et al. [37] reported off-target binding of AV-1451 in
neuromelanin-containing cells from the substantia nigra
of PSP cases. This was confirmed by Lowe et al. [31],
Fig. 3 Chemical structures of the main tau-specific radiotracers. [18F]THK5117: 2-(4-methylaminophenyl)-6-[(3-[18F]-fluoro-2-hydroxy)propoxy]quinoline;
[18F]THK5317: (S)-2-(4-methylaminophenyl)-6-[(3-[18F]-fluoro-2-hydroxy)propoxy]quinoline; [18F]THK5351: (S)-2-(4-methylaminopyridyl)-6-[(3-
[18F]-fluoro-2-hydroxy)propoxy]quinoline; [18F]T808: 2-(4-(2-[18F]-fluoroethyl)piperidin-1-yl)benzo[4, 5]imidazo[1,2-a]pyrimidine; [18F]AV-1451:
(7-(6- fluoropyridin-3-yl)-5H-pyrido[4,3-b]indole; [11C]PBB3: (5-((1E,3E)-4-(6-[11C]methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)benzo[d]thiazol-6-ol;
[18F]MK-6240: 6-([18F]-fluoro)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine
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who more generally reported off-target binding in melanin-
containing and vascular structures, as well as in the
midbrain, meninges, scalp and basal ganglia in all cases, re-
gardless of disease type. All structures reported to be specif-
ically targeted by the tau tracers are summarized in Table 2.
Overall, while all the tracers discussed here show
good affinity for tau, the type of tau deposits (con-
formation, maturation stage, what tau isoform, etc.)
and their specific binding site(s) are not yet fully
known. The reported off-target binding may also rep-
resent a major limitation for interpretation of signal
detection in vivo.
Preclinical in vivo characterization in animal models using
micro-PET imaging
PET imaging in animals has been used to investigate the
in vivo pharmacokinetic properties of newly developed tau
PET tracers in wild-type mice, rats and monkeys, and in
various transgenic mouse models expressing human tau.
Wild-type animal models: Cerebral retention of tau
tracers in wild-type mice was investigated using micro-
PET for all three families of tracers. All tracers showed
rapid uptake and washout, indicating favorable pharma-
cokinetic properties [15, 18, 26, 28]. Because of its better
binding properties and more rapid kinetics, the more
recently developed [18F]THK5351 had a higher signal-
to-background ratio than [18F]THK5117 [26]. Of note, a
recent micro-PET study in wild-type mice investigated
the effect of chirality on the kinetic properties of
[18F]THK5105 (antecessor tracer). The authors showed
that while both enantiomers had similarly fast initial
uptake, the (S)-form had a more rapid washout, and there-
fore more favorable kinetics, than the (R)-form [32]. Inter-
estingly, the difference between enantiomeric forms was
more prominent in vivo than in corresponding ex vivo
studies, possibly because of the effects of anesthesia on
metabolism, according to the authors.
Steady accumulation of [18F]AV-1451 in bone was re-
ported, probably due to defluorination of the tracer [18].
Possible off-target binding of [18F]AV-1451 was also in-
vestigated in the Rhesus monkey, using self-blocking
(preinjection of a high dose of unlabeled AV-1451 prior
to injection of [18F]AV-1451) [23]. Although this animal
model did not exhibit tau pathology, the authors ob-
served a significant decrease with time in the retention
of [18F]AV-1451 throughout the brain, reflecting off-
target binding of the tracer; further experiments sug-
gested that this observation may have been due to
binding to monoamine oxidase A (MAO-A). To fur-
ther investigate in vivo the pharmacokinetic properties
of these tracers in the presence of tau deposits, several
studies have tracked the regional distribution and tem-
poral evolution of tau pathology in small animal trans-
genic models expressing hyperphosphorylated tau.
Transgenic animal models: All of the discussed tau
tracers have been investigated in distinct transgenic models.
Micro-PET imaging was used to investigate the binding of
Table 2 Targets of the tau tracers
PBB3 THK5117 THK5351 AV-1451
Binds to NFTs [28] (ghost tangles and
non-ghost tangles [33]);
neuropil threads [28, 33];
neuritic plaques [28, 33] and
primitive plaques [33];
dense core amyloid plaques
and diffuse amyloid-beta deposits [33];
Pick bodies [28];
astrocytic plaques [28];
tau inclusions in PiD, PSP and CBD [28]
PHFs tau [125];
NFTs[15, 24, 125](both intracellular
and extracellular and ghost tangles
[125]);
neuritic plaques [125];
argyrophilic grains [125];
argyrophilic threads [125];
globose tangles [125]
NFTs [26];
thread-like structures
in the white matter
[35];
tufted astrocytes [36]
PHFs tau [18, 31, 37];NFTs [23, 37]
(both intracellular and extracellular
[37], mature tangles [31] and ghost
tangles [31, 33, 37]);
neuritic plaques and primitive
plaques [33] (to a limited extent);
dense core amyloid plaques [33];
melanin-containing structures [31, 37];
lipofuscin-containing structures [31];
mineralized structures [31];
3R + 4R tau deposits (much more
than 3R or 4R [31]);
MAO-A [23]
Does not
bind to
Pretangles [33] Pretangles [125];
alpha-synuclein lesions [125];
TDP-43 lesions [125];
Pick bodies [125]
Pretangles [125] Pretangles [33]
CBD Corticobasal degeneration, MAO-A Monoamine oxidase A, NFT Neurofibrillary tangles, PHF Paired-helical filaments, PiD Pick’s disease, PSP Progressive Supranuclear
Palsy, R Repeats (of the microtubule binding domain), TDP-43 transactive-response DNA-binding protein 43
Fig. 4 Comparison between [3H]THK5117 binding pattern using
autoradiography and AT8 immunostaining. Experiments were
performed on paraffin sections from the anterior part of the right
hippocampus of a patient with pathologically confirmed AD. This
figure was adapted from Lemoine et al., 2015 [24], with permission
from the journal
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[11C]PBB3 in the PS19 transgenic mouse model (expressing
4R tau pathology) [28], and the binding of [18F]THK5117
in two other mouse models with MAPT mutations: P301S
(Tau-P301S) and biGT (bigenic GSK-3β x Tau-P301L) [39].
Both studies reported higher tracer uptake in transgenic
mice than in wild-type mice, with in vivo retention signifi-
cantly correlating with the corresponding in vitro patterns
on autoradiography and AT8 immunostaining. In contrast,
when [18F]AV-1451 retention was investigated using in vivo
micro-PET in the APPSWE-Tau transgenic mice (carrying
the human P301L tau mutation), cerebral retention was
similar to that in wild-type mice [18], suggesting that
these tracers do not bind to the tau aggregates present
in these models.
One major drawback with these investigations is that dif-
ferent tracers were tested using different transgenic models,
which precludes the comparison of the different studies
and tracers. Additional limitations are inherent in the use
of animal models per se. For instance, [18F]AV-1451 did not
show significant retention when investigated in APPSWE-
Tau mice [18]. Similar findings were reported for [18F]T808
in another transgenic mouse model of tau, also expressing
P301L [29]. It was previously reported that the P301L
mutation in transgenic mice only affects the 4R (and
not the 3R) isoform of tau, and that the tau deposits
in this model look structurally different from those in
human AD pathology [40]. In addition, differences in
post-translational modifications are likely to occur
between mice and humans. The absence of [18F]AV-
1451 binding in the APPSWE-Tau mouse model was
thus probably due to its low affinity for 4R isoforms,
and/or the mouse model not being suitable for investi-
gating tau PET tracer binding in human tauopathies.
Future in vitro studies investigating the type of tau
deposits targeted by each tracer would greatly aid in
the selection of mouse models appropriate for com-
parison of in vivo binding of the different tracers.
In vivo kinetic modeling in humans
In vivo kinetic modeling studies have been performed with
tau PET tracers in humans, with the aim of determining an
optimal method for quantifying tau retention. Because of
the discernable interest in the clinical applicability of tau
PET imaging, there is a need for quantification methods
that can be easily transposed to the clinic. Though in vivo
kinetic models using arterial sampling are the “gold stand-
ard” for accurate quantification of the pharmacokinetic
properties of PET tracers, several studies have tested less-
invasive quantification methods (i.e. without arterial sam-
pling), using reference tissue models, more suited for use in
clinical settings. In this respect, studies have also looked to
validate semi-quantitative approaches such as the use of
standardized uptake value ratio (SUVR), and to determine
the optimal time interval for quantification.
Kinetic modeling in humans has been studied for all
tracers (including the (S)-form of [18F]THK5117:
[18F]THK5317, but not the racemic form) [41–46],
and arterial sampling has also been used for all of them
[43, 44, 46–48], except [18F]THK5351. These studies
aimed at validating the optimum late-phase SUVR interval
so as to quantify tracer retention. Cerebellar regions were
selected as the reference tissue in all reference-tissue
models because they are relatively spared from tau
deposits in AD until late in the disease course [2]. De-
tails of the findings are summarized in Table 3. An
additional study reported the early-phase SUVR inter-
val of [18F]THK5317 as a suitable proxy for brain per-
fusion [49].
The plasma-input Logan model was found to be suit-
able for determining retention of both [18F]AV-1451 and
[18F]THK5317 [43, 44, 47]. The two-tissue compartment
model (2TCM) was also reported as suitable in some
studies [43, 44]. However, after testing different plasma-
input compartment models, only dual-input models that
took brain metabolite activity into account were found
to be suitable for accurate quantification of [11C]PBB3
[46]. The reference-tissue model showing the best cor-
relation with the output from plasma-input models for
[18F]AV-1451 and [18F]THK5317 was the reference
Logan model [44, 47]. For [11C]PBB3, despite the pres-
ence of radiolabelled metabolites capable of crossing the
blood brain barrier, the multilinear reference tissue
model (MRTMo) showed good correlation with the
dual-input model [46]. Finally, different studies for every
PET tracer investigated SUVR quantification. While
there were some reservations about its use with [18F]AV-
1451 because of nonlinear associations between SUVR
values and reference-tissue model-derived parameters
with this tracer [41], a recent study reported good cor-
relation between SUVR over 80–100 min (the optimal
time-window for all other studies) and plasma-input kin-
etic model-derived parameters [48].
Overall, the possibility of using, for all tracers, reference-
tissue models and SUVR values as suitable measurements
of in vivo binding is of great value for future applicability in
clinical settings.
Other tau-specific tracers under preclinical evaluation
Additional tracers that appeared to be promising candi-
dates for targeting tau deposits using PET include benz-
imidazole (lansoprazole and astemizole) [50], BF-126 or
quinolone derivatives (BF-158 and BF-170) [51]. Recent in
vitro experiments using the novel pyridine isoquinoline
amine derivative MK-6240, released by Merck laborator-
ies, have shown high affinity for NFTs, poor binding to Aβ
plaques, and good grey matter/white matter binding ratios
in autoradiography studies [23, 52]. Comparison with
[3H]AV-1451 in autoradiography studies showed that
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[3H]MK-6240 provided greater contrast in binding
between the hippocampus and subcortical regions and
no off-target binding, and suggested that MK-6240 and
AV-1451 might be competing for the same binding site.
In vivo PET studies in the Rhesus monkey reported that
[18F]MK-6240 displayed both rapid brain uptake and
washout, indicating favorable tracer kinetics, and was
also distributed homogeneously because of the negligible
amount of tau in the Rhesus monkey brain [23, 52].
Further in vivo studies using self-blocking in the Rhesus
monkey confirmed the absence of off-target binding in all
brain regions for [18F]MK-6240, contrarily to [18F]AV-
1451 [23]. Further investigation of these tracers in various
tauopathies is needed, both in vivo and in vitro.
In vivo assessment of tau using PET
In vivo assessment in cognitively normal individuals
In order to assess the specificity of tau radiotracers in vivo,
PET studies have investigated their retention pattern in
healthy subjects. Tau PET studies in cognitively normal
(CN) elderly individuals using [18F]THK tracers have
shown that cortical retention, although above reference
levels, was relatively low and mainly confined to the med-
ial aspect of the temporal lobe [45, 53]. Similar cortical
findings were obtained using [18F]AV-1451, with all stud-
ies conducted thus far showing some degree of retention
located within temporal regions [54–65].
In all these studies, however, locally high tracer reten-
tion was seen in a number of cerebral regions in CN sub-
jects, both elderly and young, which seems to be off-target
binding. For instance, studies have shown extensive in vivo
binding of [18F]AV-1451 and [18F]THK tracers in the mid-
brain and basal ganglia, and of [18F]AV-1451, but not for
[18F]THK5351, in the choroid plexus of CN subjects
[26, 45, 53, 61]. As reported in in vitro studies (see
above), this is likely to reflect off-target binding to vari-
ous entities such as MAO-A [23], or pigmented or
mineralizad vascular structures [31, 37]. In addition,
high subcortical retention in the white matter was
noted with [18F]THK5117, probably as a result of nonspe-
cific binding to β-sheet structures present in myelin basic
proteins [30]. This was greatly diminished, however, with
the (S)-form of the tracer, [18F]THK5317, and with the
more recently developed [18F]THK5351 [26, 53]. Lastly,
high retention of [11C]PBB3 was reported in the dural
venous sinuses of CN subjects [28]; it is not yet clear, how-
ever, whether this reflects off-target binding.
In vivo assessment in Alzheimer’s disease
Several clinical stages have been defined in AD, including
preclinical, symptomatic pre-dementia (prodromal), and
dementia. With the development of molecular imaging,
specific diagnostic criteria integrating amyloid PET imaging
have been recently proposed to better define these stages
[66, 67]. It seems, however, that amyloid PET imaging alone
does not discriminate well between symptomatic (pro-
dromal and demented) stages of AD. There is thus a strong
interest in investigating the regional retention of tau PET
tracer in vivo at different stages of the pathology.
In patients with Alzheimer’s disease dementia: A fast
growing number of in vivo studies aimed to assess the
retention pattern of tau PET tracers in patients with a
diagnosis of probable AD, in comparison to CN individ-
uals. Most of the published studies in humans have thus
far focused on the THK tracers or [18F]AV-1451; one
study compared the in vivo retention of the radiotracer
[11C]PBB3, however, in three patients with AD dementia
and three CN subjects [28], reporting higher tracer accu-
mulation in patients compared to controls in several
brain areas, predominantly medial temporal regions.
The first THK radiotracers developed (the racemic forms
of [18F]THK523, [18F]THK5105, and [18F]THK5117)
showed important limitations, such as substantial over-
lap between clinical groups [68, 69] or high retention in
white matter [30, 68, 69], which precluded simple visual
assessment and prevented their future use in clinical
settings. So far, the most promising radiotracers from this
family appear to be [18F]THK5317 and [18F]THK5351. In
vivo studies in AD dementia patients using these tracers
have shown cortical uptake matching the distribution of
tau deposits reported from histopathological studies, with
retention in the inferior temporal region providing the best
discrimination between patients and CN subjects [26, 53].
[18F]THK5351, however, has more favorable pharmacokin-
etics, less white matter binding, and a higher target-to-
reference signal than [18F]THK5317 [70]. Other groups
using [18F]AV-1451 in vivo substantiated these findings by
reporting good discrimination between AD dementia
patients and CN subjects, with greater cortical reten-
tion in patients, mostly within the temporal cortex
[22, 45, 56, 59, 61]. The pattern of cortical retention in
patients was again in agreement with the expected
pattern of tau deposition in AD. Across studies, reten-
tion was predominant in the temporal cortex, with the
inferior temporal gyrus appearing to be the best region
for discriminating between AD dementia patients and
CN subjects (Table 4).
There is also an interest in the relationship between
the patterns of tau deposition assessed in vivo and the
symptomatology of clinical variants of sporadic AD, such
as posterior cortical atrophy, logopenic variant of primary
progressive aphasia, or behavioral/dysexecutive variant.
Pathological studies have indicated that while these atyp-
ical forms share the pathological hallmarks of AD, they
present with distinct neurodegenerative patterns, match-
ing the symptomatology [71, 72]. Case series describing
the retention of [18F]AV-1451 in vivo in posterior cortical
atrophy, logopenic variant of primary progressive aphasia,
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and a behavioral variant of AD [61, 73, 74] as well as in
one non-amnestic AD patient [61], have reported a neuro-
anatomical correspondence between the retention of the
tracer and the clinical presentation for all variants, with
[18F]AV-1451 retention most prominent in the clinically
affected regions.
In prodromal Alzheimer’s disease and mild cognitive
impairment: Beyond the ability to discriminate AD de-
mentia patients from CN subjects, a major challenge
for tau radiotracers is their efficacy as early biomarkers,
that is, their use as a sensitive tool for detecting early
stages of AD tau pathology. In a recent study using
[18F]THK5317, the authors reported that not only
patients with AD dementia but also prodromal AD
patients (patients with mild cognitive impairment –
MCI – and positive Aβ PET) had significantly greater
cortical retention than CN subjects [53]. There was
however no statistical difference between prodromal
AD and AD dementia patients in this sample, although
a greater proportion of patients with AD dementia
showed high [18F]THK5317 retention in cerebral regions
that are expected to be affected by tau pathology only late
in the disease course. Other studies have reported that
[18F]AV-1451 retention best discriminated MCI patients
from CN subjects in mesial temporal regions (parahippo-
campal cortex, and entorhinal cortex) [56, 59]. As for the
hippocampus, interestingly, some authors reported signifi-
cant group differences [56] while others did not [59]. This
discrepancy was probably due to differences between the
studies in quantification methods and the studied popula-
tions: other than the differences in recruitment criteria,
not all MCI patients in these two studies were amyloid
positive (77 and 67%, respectively), meaning that a signifi-
cant proportion were unlikely to be at an early stage of
AD. In addition to these findings, Pontecorvo et al. [75]
reported that younger AD patients (i.e. under 75) had
greater [18F]AV-1451 cortical retention than older AD
patients, and Cho et al. [57] reported that patients with
early-onset AD (i.e. < 65 years) had greater [18F]AV-
1451 cortical retention than patients with late-onset
AD, as described in post-mortem histopathology studies
on NFTs and neuritic plaques [76]. Of note, the same
off-target binding reported in CN subjects was also ob-
served in AD patients for all tracers [26, 28, 53, 61].
Relationship between the retention of the tracers and
clinical impairment: Several studies using [18F]AV-1451
or THK radiotracers have started investigating the re-
lationship between the regional tracer retention and
concomitant cognitive performance in AD patients.
They have reported a significant negative relationship
between global cortical tracer retention and global
cognitive status [56, 68], and also between retention in
the temporal cortex and global cognition [30, 59, 77].
One longitudinal study also reported a significant positive
relationship between increased [18F]THK5117 retention in
the temporal cortex and cognitive decline [78]. Retention
in the temporal cortex was also found to correlate with
memory impairment in AD patients (across both pro-
dromal and dementia stages) [57, 77]. Specifically, it ap-
pears that worse performance on domain-specific tests
was associated with greater retention in key regions im-
plicated in the involved cognitive domain [56, 61].
In preclinical Alzheimer’s disease: Conceptual and bio-
marker advances over the past decade have led to the
identification of a preclinical phase of AD, recently for-
malized by new diagnostic criteria that integrate bio-
markers for brain amyloidosis (i.e. CSF Aβ42 and Aβ PET)
and neurodegeneration (CSF tau, regional atrophy, and
[18F]fluorodeoxyglucose ([18F]FDG) PET) [66, 67, 79, 80].
Though these criteria for preclinical AD have not been
formally applied in all studies that have thus far used tau
PET imaging to investigate CN older adults, Aβ-negative
subjects had only localized increases in medial temporal
lobe retention, while Aβ-positive subjects, believed to be
within the AD preclinical pathway, showed more exten-
sive tracer retention, including in AD signature regions
[54, 64]. Comparison between Aβ-positive and Aβ-
negative subjects, however, showed no group differences
in hippocampal retention [64]. A further study involving
sub-classification of subjects into preclinical stage 1 (Aβ-
positive, neurodegeneration-negative) and preclinical stage
2 (both Aβ- and neurodegeneration-positive) showed
higher [18F]AV-1451 retention in medial temporal regions
at both stages 1 and 2, relative to Aβ-negative and
neurodegeneration-negative subjects (stage 0), and higher
levels in the inferior temporal gyrus at stage 2, relative to
stages 0–1 [60].
Of note, a highly interesting population to study pre-
clinical stages of AD in is presymptomatic individuals
carrying mutations involved in autosomal dominant AD.
These individuals have been the focus of many research
groups over the past years, as they will eventually de-
velop AD, and thus offer the opportunity to assess in
vivo the progression of pathological features before the
onset of symptoms [81, 82]. There are to date, however,
no published reports on tau PET in presymptomatic
cases of autosomal dominant AD.
In vivo assessment in non-AD proteinopathies
CBD and PSP, two diseases in the spectrum of frontotem-
poral lobar degeneration, which are characterized by
atypical parkinsonism and substantial clinicopathological
overlap [83, 84], have received increased attention with the
emergence of tau PET imaging. Both diseases are character-
ized by the deposition of abnormally hyperphosphorylated
tau, mostly 4R, in tubular or straight filaments, in contrast
to the PHFs in AD. Moreover, the spatial distribution of tau
deposits in these diseases is distinct from that seen in AD
Saint-Aubert et al. Molecular Neurodegeneration  (2017) 12:19 Page 11 of 21
[85, 86]. High tau deposition (measured with [18F]AV-1451,
[18F]THK5317 or [18F]THK5351 PET) was observed in pa-
tients with a clinical diagnosis of PSP, in areas expected
based on the neuropathological literature: the basal ganglia,
thalamus, dentate nucleus of the cerebellum, and midbrain
[36, 53, 87–89]. The association between [18F]AV-1451 re-
tention in the basal ganglia and clinical deterioration in
these PSP patients was not consistently reported. Concord-
ance with pathological patterns of tau deposition was also
found in patients with CBD: case-reports of Aβ-negative
patients with clinical diagnoses in the CBD spectrum re-
vealed increased tau deposition, as measured by [11C]PBB3,
[18F]THK5317 and [18F]THK5351, predominantly in white
matter and the basal ganglia, but also in other cortical areas
[28, 35, 53].
Dementia with Lewy bodies and Parkinson’s disease are
characterized by the presence of α-synuclein aggregates,
although the presence of tau deposits similar to those in
AD pathology are also commonly found [90–92]. [18F]AV-
1451 retention in patients with dementia with Lewy bod-
ies and Parkinson’s disease-related cognitive impairment,
but not in cognitively unimpaired Parkinson’s disease pa-
tients, was found to be higher than in controls, although
greatly variable [93]; the [18F]AV-1451 retention was nega-
tively related to global cognitive function but not to the
concomitant Aβ load. Another study comparing patients
with dementia with Lewy bodies and patients with AD de-
mentia reported a much lower cerebral retention of
[18F]AV-1451 in AD, and revealed that the retention in
the medial temporal lobe could discriminate between the
two disease groups [94]. Though further studies are re-
quired, and while keeping in mind that the clinical distinc-
tion between dementia with Lewy bodies and AD can be
challenging, these findings highlight the potential utility of
tau imaging in the context of differential diagnosis.
Following a different approach, Hansen et al. and Cho et
al. [88, 95] took advantage of the reported off-target bind-
ing of [18F]AV-1451 to neuromelanin [37], and aimed at
imaging the loss of dopaminergic neurons in the substan-
tia nigra of patients with Parkinson’s disease [88, 95].
Lower [18F]AV-1451 nigral retention was observed in pa-
tients with Parkinson’s disease, in comparison to a control
group, although the overlap between patients and controls
limits the clinical translation of the findings. Further, ni-
gral retention in patients with Parkinson’s disease did not
correlate with dopamine transporter levels in the basal
ganglia (measured by [123I]FP-CIT single photon emission
computed tomography), motor disability, age, or time
since diagnosis.
In vivo retention of [18F]AV-1451 was also assessed in
cases carrying mutations of the MAPT gene: Bevan-
Jones et al. [96] described, in a patient with familial fron-
totemporal dementia due to a MAPT mutation (MAPT
10 + 16C > T), a retention pattern in agreement with the
regional pattern of 4R tau pathology observed in the
brain of the deceased father, carrier of the same muta-
tion. Smith at al. [97] studied the in vivo retention of
[18F]AV-1451 in three symptomatic patients (two with
MCI, one demented) carrying a MAPT mutation (p.
R406W); the latter mutation is pathologically character-
ized by the presence of cortical NFTs. Here again, the
[18F]AV-1451 retention pattern was in agreement with
reported post-mortem findings on tau deposits, showing
involvement of temporal and frontal regions with spar-
ing parietal and occipital lobes [98]. The authors sug-
gested a progression pattern of tau in this mutation,
although this requires further investigation in studies
with a longitudinal design and larger sample sizes.
Taken together, these studies suggest that the developed
tau PET tracers can image the expected regional distribu-
tion of tau pathology outside the AD spectrum, especially
in tauopathies. This is, however, at odds with in vitro find-
ings mentioned earlier, which suggests that [18F]AV-1451
might not bind substantially to, or might bind only to a
small fraction of, the 4R tau burden [31, 37].
In vivo assessment in suspected non-AD pathophysiology
Operationalization of the National Institute on Aging-
Alzheimer’s Association (NIA-AA) criteria for preclinical
AD [79] led to the identification of Aβ-negative CN indi-
viduals with positive neuronal injury biomarkers [99]. Be-
lieved to represent non-AD etiologies, this group has been
labeled “suspected non-AD pathophysiology” (SNAP).
SNAP is thought to represent the in vivo equivalent of the
recently described “primary age-related tauopathy”
(PART), a concept currently under debate [100], intro-
duced to describe the frequent observation in autopsy
studies of focal NFTs pathology, despite the absence or
minimal presence of Aβ plaques [101]. Several investiga-
tions using tau PET have made reference to SNAP as a
possible explanation for the high percentage of Aβ-
negative cases in CN individuals with an estimated Braak
stage of I-II [56] and for focally elevated cortical [18F]AV-
1451 retention [57, 63]. Additional studies have described
cases possibly representative of PART [62, 95], although
these also raised the possibility that AD pathology might
be masking PART in preclinical individuals, with Aβ path-
ology below the detection threshold of Aβ PET imaging.
Findings from the Harvard Aging Brain Study, however,
do not support the hypothesis that SNAP is the in vivo
counterpart of PART, as mean retention of [18F]AV-1451
within the medial temporal lobe among SNAP individuals
was almost identical to that seen in stage 0 subjects (CN,
Aβ- and neurodegeneration-negative) and lower than
levels in subjects at preclinical stages 1–2 [60]. Import-
antly, this study highlights discordance between tau PET
and neurodegenerative biomarkers used to define SNAP
(i.e. hippocampal volume and [18F]FDG PET), a finding
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that carries implications for staging criteria for both SNAP
and preclinical AD.
Staging based on tau PET
To date, three cross-sectional studies have attempted to ex-
plore the spreading pattern of [18F]AV-1451 tau PET reten-
tion while translating the post-mortem staging system of
tau pathology in AD from Braak and Braak [2] to in vivo
staging models [54, 56, 62]. Secondary aims of these studies
included exploring the relationship between these esti-
mated in vivo Braak stages, other biomarkers (including
amyloid PET and grey matter changes), and cognition.
All three studies included both CN and cognitively
impaired individuals and employed either classification
models or thresholds for classifying individuals with abnor-
mal [18F]AV-1451 tau PET retention in selected regions of
interest (ROIs). Measurement of the prevalence of abnor-
mal [18F]AV-1451 retention (defined as [18F]AV-1451 posi-
tivity) in these ROIs indicated that the medial temporal
lobe was the region most prominently affected across par-
ticipants, followed by the adjacent temporal neocortex, the
neocortical association areas and, the primary cortices [56],
consistent with the stereotypical progression of tau path-
ology described by post-mortem studies [102]. Based on
[18F]AV-1451 positivity in the selected ROIs, the authors
assigned theoretical Braak stages to the participants. Ac-
cording to that staging, the majority of symptomatic indi-
viduals with a positive Aβ PET scan (Aβ-positive MCI or
AD patients) were classified as Braak stage V-VI [54, 56,
62]. Surprisingly, however, a relatively large number of Aβ-
positive MCI patients were classified as Braak stage 0 in
one study [62]. Of note, not all patients could be staged in
the theoretical models [56, 62], as also occurs with neuro-
pathological evidence [2], and these were classified as “vari-
ants”; most variants were Aβ-positive [62]. Taking into
account both CN and cognitively impaired individuals, the
estimated Braak stage was associated with cognitive per-
formance [56, 62]. Moreover, in a large group of young and
elderly CN subjects, [18F]AV-1451 retention in ROIs
created to match the neuropathological “Braak” stages was
related to poorer cross-sectional memory and global cogni-
tive performance, as well as to retrospective longitudinal
cognitive decline [54].
The generalizability of these results is subject to im-
portant limitations, however. Firstly, all observations
were based on cross-sectional data used to describe a
longitudinal process. Secondly, the methods used to
define the thresholds for tau positivity varied among the
studies, and were data-driven, based on a limited num-
ber of control individuals from the same study: thus,
threshold calculations require validation in separate co-
horts. Thirdly, the low spatial resolution of PET and the
off-target binding of [18F]AV-1451 could limit accurate
staging of the hippocampal formation. Lastly, the
classification of a large number of symptomatic individ-
uals with a positive Aβ PET scan to Braak stage 0 [62]
raises questions about either the accuracy of clinical as-
sessment or the in vivo translation of the neuropatho-
logical staging scheme.
Relation of tau PET to other biomarkers and
apolipoprotein E
The time course of tau aggregation and its dynamic rela-
tionship to other pathophysiological features in the vari-
ous tauopathies remain unclear. The theoretical models
of disease progression including tau pathology were so
far restricted to CSF-based measures of tau [103]. With
the availability of tau PET tracers, several studies have
started to investigate the relationship between regional
tracer retention and other biomarkers in their popula-
tion sample. Because several studies have combined CN
subjects with patients in their analyses, sometimes limit-
ing interpretation of the results, we have limited this
discussion mainly to findings for patients alone or CN
subjects alone.
Amyloid PET
Studies in AD dementia patients have shown differences
in the topographical retention of tau and Aβ tracers: in
contrast to [11C]PIB, which had widespread cortical reten-
tion, the retention of THK tracers was more focal, pre-
dominantly within the temporal lobe (Fig. 5) [53, 104].
Other studies involving atypical variants of AD have also
contrasted the focal cortical retention observed with
[18F]AV-1451 to the more widespread and diffuse reten-
tion of [11C]PIB [61, 73, 74]. Other than these topograph-
ical differences, while no association was found between
the cortical retention of [18F]THK5117 and [11C]PIB
in AD dementia patients [104], positive correlations
have been reported between local [18F]THK5317 and
[11C]PIB retention in prodromal AD and AD dementia
patients [53], as well as between temporal [18F]AV-
1451 and global cortical [11C]PIB retentions in pa-
tients with MCI or AD dementia [59], suggesting the
possible temporal proximity of the build-up of these
two pathological processes.
[18F]FDG PET
Initial studies have reported a close correspondence
between the selective retention pattern of [18F]AV-1451
PET and the pattern of hypometabolism with [18F]FDG
PET in case series of patients with variants of AD (Fig. 5)
[61, 73, 74]. Group level analysis in prodromal AD and
AD dementia patients has revealed similar findings [105];
[18F]FDG uptake and [18F]THK5317 retention appear to
be negatively correlated, primarily in frontal areas [53].
Interestingly, exploratory work on the same sample has
suggested that [18F]FDG might play a mediating role in
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the association between tau pathology and cognitive de-
cline in AD [77]. In addition, one study using [18F]AV-
1451, [18F]FDG and [11C]PIB PET in AD patients sug-
gested an interactive downstream effect of regional tau
and Aβ on metabolism in the parietal lobe [105]. The
small sample size, however, precludes any strong
conclusions.
Structural measures
The in vivo relationship between [18F]AV-1451 retention
and grey matter intensity measured by structural magnetic
resonance imaging (MRI) was analyzed in a sample of CN
subjects. A negative correlation was found, using both
local (medial temporal lobe, cingulate) and distributed
(widespread cortical regions) approaches [63]. Interest-
ingly, a study by Wang et al. [64] reported that Aβ status
appeared to affect the association between [18F]AV-1451
retention and cerebral volume; only Aβ-positive partici-
pants (CN subjects and AD patients) showed a significant
association between tau imaging and volume loss. This
suggests that the relationship between tau deposition and
neuronal loss will only be observed in a pathological con-
text, and highlights the importance of discriminating
between CN subjects who are likely to be at a preclinical
stage of AD, and those who are not.
Cerebrospinal fluid measures
Until recently, the only way to obtain information on
tau protein in vivo was to use CSF sampling. A large
number of studies have investigated the progression of
CSF tau biomarkers in AD, showing a relationship
between tau levels and the rate of cognitive decline
[106]. Longitudinal studies on autosomal dominant AD
reported that elevated CSF tau could be measured
decades before the onset of symptoms [107]. The same
research group also reported an unexpected finding that
CSF tau level declined slightly at symptomatic stages in
their studied population. Because of discrepancies re-
ported in Aβ measurement between CSF sampling and
PET imaging [108], a comparison of CSF tau levels with
the newly developed tau tracers is thus of great interest.
In a study of CN subjects only, significant associations
were found between both CSF total and phosphorylated
tau and [18F]AV-1451 retention in the temporal cortex
[109]. Retention in other regions was associated with
phosphorylated tau only. Conversely, another study re-
ported no significant associations between either total or
phosphorylated CSF tau and [18F]AV-1451 retention in
the inferior temporal lobe in CN subjects [58]. However,
significant positive associations were found when AD
dementia patients were included in the analyses (in com-
bination with CN subjects) [55, 58]. This calls for future,
Fig. 5 In vivo imaging of AD biomarkers in a patient with prodromal AD and in a patient with AD dementia. The retention of [18F]THK5317 and
[11C]PIB are expressed with reference to the retention in the grey matter of the cerebellum; [18F]FDG uptake is expressed with reference to
uptake in the pons. AD = Alzheimer’s disease; DVR = distribution volume ratio; FDG = fluorodeoxyglucose; PIB = Pittsburgh compound B;
SUVR = standardized uptake value ratio
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larger studies in patients. Of note, Chhatwal et al. [109]
also reported that lower CSF Aβ42 in their CN subjects
correlated with higher [18F]AV-1451 retention in neocor-
tical but not limbic regions of the temporal lobe.
Apolipoprotein E
The apolipoprotein E (ApoE) ε4 allele is a well-known
risk factor for developing AD. Preliminary findings on
the relationship between the retention of tau tracers and
ApoE ε4 status are rather discordant. In one study of
AD patients, ApoE ε4 carriage was associated with
[18F]AV-1451 retention in temporal and parietal areas,
after controlling for global Aβ levels [61]. While this is
consistent with findings from Cho et al. [57], which
showed that the frequency of the ApoE ε4 allele was
associated with higher [18F]AV-1451 retention in medial
temporal regions in MCI and AD dementia patients,
another study of MCI and AD dementia patients did not
find an association between ApoE ε4 carrier status and
[18F]AV-1451 retention [59].
Assessment of tau deposition in vivo in multimodal
paradigm has raised great expectations for the under-
standing of the role of tau with relation to other patho-
logical features. While preliminary, these promising
studies indicate the first steps toward that goal and lay
the groundwork for the testing of additional hypotheses
relating to how the combination of tau imaging with
other existing biomarkers may help increase diagnostic
accuracy. One apparent limitation of these studies inves-
tigating the relationship between tau PET and other
biomarkers, however, is that they are based on cross-
sectional data, which limits interpretation of how these
relationships may evolve over time.
Post-mortem/ante-mortem comparison in humans
To date, five studies comparing ante-mortem tau tracer
binding results with post-mortem findings have been per-
formed in humans. All used [18F]AV-1451 in patients with
non-AD pathology [97, 110–113]. In their study, Marquié
et al. [111] compared the regional in vivo ante-mortem
binding of [18F]AV-1451, its post-mortem binding on auto-
radiography, and tau immunostaining in three cases with
4R tau aggregates: two patients with pathologically con-
firmed PSP, and one patient with a MAPT mutation
(P301L) presenting with an unusual histopathological
phenotype of abundant cortical and white matter small
grain-like tau inclusions instead of the expected NFTs and
neuritic processes. The authors reported no detectable
binding of [18F]AV-1451 to tau inclusions in these three
cases, however, and no significant correlations between in
vivo and in vitro binding, despite in vivo signal in basal
ganglia, midbrain, and some cortical regions. A similar
observation was made by Smith et al. [113] in a case of
PSP, where they found that the density of tau pathology
on immunostaining correlated with in vivo metabolism
(measured with [18F]FDG PET) but not with in vivo
[18F]AV-1451 binding. These findings suggest that the
signal observed in vivo is more likely due to the pres-
ence of age-related tangles and off-target binding than
to specific binding of the tracer to 4R tau aggregates.
Of note, these observations regarding the MAPT muta-
tion carrier also confirm the in vivo micro-PET findings
mentioned earlier in the APPSWE-Tau transgenic mice
model (carrying the human P301L tau mutation) [18].
Another case study on a MAPT mutation carrier did
show good agreement between ante-mortem binding of
[18F]AV-1451 in PET and post-mortem tau immunohis-
tochemistry results [97]. This case, however, carried a
different MAPT mutation (R406W) with 3R + 4R tangles
and neurites, rather similar to AD pathology. The region
with the highest [18F]AV-1451 retention in vivo in this
case was the putamen. This region also exhibited dense
tau pathology on post-mortem assessment, but less than
in other regions such as the inferior temporal lobe,
which reinforces the hypothesis of non-specific in vivo
tracer binding in this region [97].
The two last studies comparing ante-mortem and post-
mortem findings relied on single cases with a confirmed
diagnosis of CBD (4R tau deposits) [110, 112]. Both studies
reported a correlation between regional in vivo binding of
[18F]AV-1451 and post-mortem tau immunostaining. How-
ever, Josephs et al. [110] reported minimal displaceable
binding of [18F]AV-1451 on autoradiography in areas with
dense 4R tau deposition (in agreement with other studies
[31]), which contrasted with their in vivo observations in
the same case. This again calls into question the binding
properties of the tracer with respect to 4R tau pathology.
It appears, overall, that [18F]AV-1451 may not have
enough affinity and therefore may be of limited utility for
in vivo detection of tau aggregates in non-AD tauopathies.
Further investigations in larger samples are required to
confirm these findings.
Future directions
This review summarizes the recent literature on the cur-
rently most promising families of tracers for specifically
targeting tau in vivo. Both preclinical and early in vivo
PET findings are encouraging, showing good specificity
for tau and regional distribution that matches the ex-
pected pattern of tau pathology. Further work, however,
is required in order to fully explain the binding proper-
ties of the tau PET tracers, and eventually to better
comprehend the role of tau deposition in vivo in the
pathophysiology of AD and other non-AD tauopathies.
Further in vitro characterization is needed
The variety and complexity of tau deposits in the various
tauopathies requires a great effort of characterization of tau
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tracers. Evidence for the specific isoforms and structural
conformations of tau to which the tracers bind remains
scarce. Important studies have provided preliminary but
crucial information about the in vitro binding of AV-1451
in different tauopathies, reporting more extensive binding
in AD brain tissue than in tissue from other diseases such
as CBD, PSP, or Pick’s disease [31, 37]. These studies
have also suggested that AV-1451 would not bind – or
would bind to a limited extent only – to 4R tau de-
posits. Similar in vitro investigations are so far lacking
for the other tau tracers. This matter requires further
work in the near future so that a similar level of
characterization is reached for all promising tracers
with respect to their binding properties.
Similarly, we need to identify the binding sites of the
tracers, along with the number of sites to which they
bind. Studies have suggested multiple binding sites on
tau for THK tracers, and already comparisons between
tracers suggest that some target the same sites (AV-1451
and MK-6240) [23] while others do not (AV-1451 and
PBB3) [33]. Future studies investigating the location and
accessibility of the binding sites in different types of tau
deposits will add information essential to our under-
standing of the tracers distribution patterns. Indeed, it is
likely that the accessibility of a given tracer to its binding
site(s) will be affected by the isoform and conformation
of tau in the targeted deposit.
Different tracers for different diseases?
Because the different tracers come from distinct chemical
families, they are likely to bind differently to tau deposits.
While all tracers described in this review have good affinity
to tangles and have shown a similar binding pattern
in vitro and in vivo in the AD brain, which also re-
sembles the pathological pattern described with im-
munostaining, discrepancies seem to exist between
the tracers in their binding to tau deposits in non-
AD cases. There is, however, very little in vitro evi-
dence with regard to the binding of tau tracers in
non-AD tauopathies, especially for THK tracers and
PBB3, and, to date, no head-to-head comparisons
between tracers (in the same patient populations),
either in vitro or in vivo. This represents an import-
ant future challenge, as such results would provide
much required understanding of tracers specificity,
and would help determine whether some tracers may
be more suitable for tracking tau deposition in some
tauopathies than in others. In addition, new tracers
currently under development or undergoing preclin-
ical assessment may have advantages over those
already described, such as lower off-target binding.
Comparison between these candidates and other tau
tracers will also be required.
Off-target binding
The off-target binding observed for all the tau tracers,
both in vivo and in vitro, is a major issue. There is cur-
rently a great effort to try to define what this off-target
may represent. The fact that some of the regions show-
ing off-target binding in vivo are regions where specific
binding would be expected in some tauopathies is of
particular concern; this is the case, for instance, for the
basal ganglia in CBD and PSP. Early evidence from in
vitro work on AV-1451 has suggested that the signal
observed in several brain regions could be due to bind-
ing to different features, such as pigmented and miner-
alized structures [31], MAO-A [23] but also MAO-B
[114, 115]. Further work to resolve the question of this
off-target binding is thus required.
The use of tau animal models
Transgenic mouse models of tau deposition offer the
potential to assess the ability of tau tracers to track
the temporal and regional deposition of tau. Based
on the few in vivo micro-PET studies thus far per-
formed, there is evidence that certain mouse models
may not be suitable for investigating the binding of
at least some of the tau tracers. Additional studies
using various mouse models to assess in vivo bind-
ing will be of great interest, and are crucially needed
for the future development and testing of novel anti-
tau therapies.
Assessment of tau propagation in vivo
In parallel with in vitro characterization studies, the large
body of work that became rapidly available on in vivo re-
tention of tau tracers in humans has provided us with
important insights into tau deposition. Studies have
attempted to stage tau progression in vivo in AD patients
by classifying individuals into PET-based Braak stages ac-
cording to the retention pattern of tau PET tracer. Future
studies using a longitudinal design as well as pathological
confirmation will be necessary for validation of these in
vivo staging models. In addition, tau PET imaging will likely
prove of use in clarifying the role of tau pathology with re-
spect to other AD biomarkers [103] and in the operationali-
zation of novel classification schemes [116]. Increasing
evidence from in vivo studies suggests that, while they do
not share the same deposition patterns, PET-measured tau
and amyloid deposition in AD are associated in various
areas of the brain. This fits with the hypothesis of a dy-
namic interaction between tau and Aβ pathology. Again,
the absence of longitudinal studies precludes us from draw-
ing conclusions, but these findings already illustrate the
potential of in vivo investigations to further our under-
standing the dynamic process of tau deposition and its
interaction with other key actors in the disease. The emer-
gence of longitudinal multimodal data in a near future
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should allow to test how the combination of tau im-
aging with other existing biomarkers may help increase
diagnostic accuracy.
As mentioned above, there has been great interest in
recent decades in studying familial forms of AD, as
these enable the investigation of biological mechanisms
occurring in the disease course even before the onset of
clinical symptoms. One case report [117] described a
high in vivo retention of [18F]AV-1451 in a symptom-
atic carrier of a presenilin-1 mutation (Thr116Asn)
[118]. While very little is known about this particular
mutation and its underlying pathology, which precludes
further conclusions, this result does offer potential for
more investigations in familial AD, particularly future
longitudinal assessments in patients in the presymp-
tomatic stages; this would certainly allow the collection
of valuable information on the role of tau in the disease
course at the earliest stages.
The opportunity of assessing the pathophysiological
role of tau in vivo in tauopathies other than AD has
stirred great interest, and promising findings have
emerged. While most come from case studies, one
study on groups of patients illustrated for the first time
the potential of regional measurement of [18F]AV-1451
retention to discriminate between two tau-related
diseases (dementia with Lewy bodies and AD) [94]. Fur-
ther replication studies in larger sample sizes are how-
ever needed. In vivo work in other diseases affected by
tau, such as chronic traumatic encephalopathy, is also
of interest, and preliminary reports have started to
emerge [119, 120]. Assessment of the specificity of the
tracers in other proteinopathies, such as TDP-43-
related diseases, will also be of interest.
Because of the novelty of tau radiotracers, most of the
work comparing their intra-individual ante-mortem and
post-mortem binding has to date used animal models.
Among the few reports on humans, discrepancies have
been reported between the in vivo and in vitro binding of
AV-1451 in cases with 4R tau deposits [110], highlighting
the important questions of how different forms of tau may
affect tracer binding, and how transposable in vitro obser-
vations are to in vivo PET. It is possible that dynamic pro-
cesses occurring in vivo, which are not possible to assess
in post-mortem tissue, may play a role. Future studies in
pathologically confirmed cases investigating the corres-
pondence between results from in vivo tau PET and post-
mortem tau staining are imperative in order to shed more
light on this matter.
In addition, there remain methodological concerns
regarding quantification in the assessment of in vivo
tau tracer retention in non-AD tauopathies. Specific-
ally, while reference-tissue models have been shown to
describe retention well over time for most tracers,
reference region selection could be an issue, as the
commonly used cerebellum can be affected by tau
pathology in some non-AD tauopathies as well as in
the later stages of AD [53]. This matter deserves more
attention, especially when larger cohorts are studied.
Harmonization of quantification methods across stud-
ies and possibly across tracers (as it is now happening
for Aβ PET with centiloid scaling [121]), will also be
required for better comparison of findings.
Tau PET versus tau CSF
Some studies, but not all, have reported an association
between regional tau PET retention and CSF tau levels.
Although exploratory, these findings seem to indicate
that, as with Aβ biomarkers, CSF and PET-based mea-
sures of tau may result from the same pathological pro-
cesses, but may not invariably mirror one another,
instead providing complementary information. These
investigations will need to be pursued in larger AD
cohorts, and possibly with new CSF assays.
The use of tau PET in clinical trials
As a pathological hallmark in AD and other tauopa-
thies, tau aggregates have been an attractive target for
immunization therapy. In the absence of efficient treat-
ments able to stop disease progression, and with the
failure of several therapies aiming to reduce Aβ load,
clinical trials focusing on the inhibition of tau aggrega-
tion have emerged [122]. While few results from such
trials are as yet available, a recent phase III study test-
ing the tau protein aggregation inhibitor Methylthioni-
nium reported no benefit from the treatment in
patients with mild to moderate AD [123]. Further re-
sults are however expected from ongoing phase II and
III trials after promising early results [124], which will
hopefully report positive effects of treatments. Along
with this increasing interest to develop novel anti-tau
therapies, there is a compelling need to incorporate
tau PET imaging as a reliable outcome measure to
evaluate drug efficacy. Therefore, as the field of tau
PET imaging advances, tau PET will become important
to evaluate the therapeutic effects of such drugs on tau
burden in the brain, and will certainly be increasingly
incorporated in future clinical trials.
Conclusions
In conclusion, the growing number of studies investigat-
ing tau PET has provided exciting and encouraging re-
sults on the usefulness of tau PET tracers in exploring
tau pathology in various diseases. New paths are now
becoming open to us, and more in-depth work is re-
quired to further our understanding of the role of tau in
AD and other tauopathies.
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